Check the price action on VPHM stock yesterday. It soared 30% to 39.24 from Thursday's closing price of 30.24. Bloomberg reported that ViroPharma was attracting buyer interest from Sanofi and Shire PLC, and it hired Goldman to seek a better buyer. Deutsche Bank analysts think that in a right situation ViroPharma could be worth as much as $52 per share.
ViroPharma has a revenue of 408 M a year, but Vertex has a revenue three time as much and a better future potential. If it can fetch 52 dollars, Vertex is worth as least 150.